Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 21.28 CNY -1.07%
Market Cap: 11.1B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
EPS (Diluted)
ÂĄ0
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
EPS (Diluted)
ÂĄ5
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
EPS (Diluted)
ÂĄ0
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
EPS (Diluted)
ÂĄ2
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
0%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Glance View

Market Cap
11.1B CNY
Industry
Pharmaceuticals

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. emerged on the healthcare scene in China with an unwavering focus on improving allergy treatments. Founded in 1992, the company has carved a niche in the bio-pharmaceutical industry by specializing in the research, development, and manufacturing of allergen-specific immunotherapeutic products. At its heart, Wolwo operates with a clear mission: to diminish the burden of allergic diseases. The company leverages cutting-edge bio-pharmaceutical technologies to produce allergen detection and treatment products, thereby offering innovative solutions to millions affected by allergic conditions. As allergies become more prevalent worldwide, Wolwo's focus on this segment positions it as a critical player in the healthcare market. Wolwo’s business model revolves around the development and commercialization of standardized allergen products. It generates revenue primarily from the sale of its patented therapeutic solutions targeting common allergens such as pollen, dust mites, and pet dander. This involves a deep dive into biotechnology, where their R&D teams continuously innovate to refine product offerings. The company has earned regulatory approvals across various regions, which significantly bolsters its revenue stream and expands its market footprint. Beyond just product sales, Wolwo actively engages in educational programs aimed at raising awareness about allergies, thus creating a well-rounded approach not only in tackling allergic diseases but also in ensuring long-term consumer loyalty and brand trust in a rapidly evolving market.

Intrinsic Value
22.63 CNY
Undervaluation 6%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.6 CNY

Based on the financial report for Sep 30, 2024, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's EPS (Diluted) amounts to 0.6 CNY.

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
13%

Over the last year, the EPS (Diluted) growth was 7%. The average annual EPS (Diluted) growth rates for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd have been -1% over the past three years , 2% over the past five years , and 13% over the past ten years .

Back to Top